Novochizol

Novochizol SA is a Swiss biotechnology company that has developed a proprietary nanotechnology based on cross-linked, biocompatible polysaccharide nanospheres. This technology quantitatively transforms single linear chitosan molecules into uniform nanoparticles, which serve as a versatile delivery system for a wide range of active ingredients, including small molecules, nucleic acids, peptides, proteins, viruses, and cells. The platform is designed to provide bioadherent, sustained, and localized release of active pharmaceutical ingredients (APIs), enabling intracellular delivery while minimizing systemic distribution. The technology utilizes the natural, biocompatible safety profile of chitosan to enhance the efficacy of therapeutic formulations.

The company’s solutions have applications across multiple sectors, including human medicine, pharmaceuticals, medical devices, diagnostics, and agriculture. In oncology, it is being researched for intratumoral delivery, while its aerosol formulations target respiratory diseases. In agriculture, Novochizol technology acts as a co-formulant that enables significant dose reductions of chemical pesticides and copper, supporting more sustainable crop production. The company engages in R&D, out-licensing, and joint ventures, and has established partnerships for initiatives ranging from immunotherapy development to agricultural innovation. Based in Monthey, Switzerland, the company operates within the life sciences ecosystem and is a member of the Swiss Biotech Association.